0.581
0.00 (-0.73%)
| Penutupan Terdahulu | 0.585 |
| Jumlah Dagangan | 155,627 |
| Harga / Pendapatan (P/E Ke hadapan) | 0.320 |
| Harga / Jualan (P/S) | 1.81 |
| Harga / Buku (P/B) | 0.240 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -5.76 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.47% |
| Nisbah Semasa (MRQ) | 0.370 |
| Aliran Tunai Operasi (OCF TTM) | -23.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 15.85 M |
| Pulangan Atas Aset (ROA TTM) | -25.32% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.53% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Citius Pharmaceuticals, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.5 |
| Purata | -1.71 |
|
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.41% |
| % Dimiliki oleh Institusi | 5.69% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Miller Financial Services Llc | 30 Jun 2026 | 130,000 |
| Asset Advisory Group, Inc. | 30 Jun 2026 | 59,011 |
| Bostonpremier Wealth Llc | 30 Jun 2026 | 28,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |